Summary -A retrospective descriptive study about the presence of metastases, epidemiological characteristics and treatment of 104 patients suffering from gestational trophoblastic disease was performed in the period from 1 st Jan, 2000 to 31 st December, 2010. Of eleven patients who were found to have metastases (10.6%), 72.7% had pulmonary metastases, 27.3 had vaginal, and one patient had both pulmonary and brain metastases. The average age was 33.9. Antecedent molar pregnancy was recorded in 63.6% patients. Invasive mole was more frequent than choriocarcinoma (63.6%). According to the World Health Organization criteria, 7 patients (63.6%) had high risk score (the average World Health Organization score was 8.4). All patients were treated by chemotherapy, the average number of courses being 1.8. Complete remission was achieved in all patients. Treatment of metastatic disease depends on multiple factors. However, combined chemotherapy is the universally accepted treatment. If chemotherapy is individualized and applied on time, the prognosis is good, even in cases with cerebral metastases.
Introduction
Gestational trophoblastic diseases (GTD) are a group of neoplastic disorders originating from the trophoblastic tissue after normal or abnormal fertilization. They are classified as hydatiform mole (complete and partial), invasive mole, choriocarcinoma and placental site trophoblastic tumor [1] . The staging of disease is based on 1) the World Health Organization (WHO) prognostic score, 2) the International Federation of Gynecology and Obstetrics (FIGO) anatomic classification and 3) clinical presentation of non-metastatic disease and metastatic one with good and poor prognosis [2] . Data on distribution of disease are obtained on the basis of physical examination, histopathological diagnosis, X-ray of the lungs, computerized tomography (CT) of the chest and brain as well as by screening the abdominal organs combined with radionuclides, intravenous urography, echosonography or CT scanning. The absence of metastases is a good prognostic factor. At the onset of disease, gestational trophoblastic diseases first invade the myometrium, vagina and lungs, while metastases to the brain and other organs develop in the subsequent course of disease [3, 4] .
Upon the introduction of chemotherapy in 1956 [5] , GTBs have become best treated gynecological malignancy, and the development of sensitive tests for β-human chorionic gonadotropin (β-hCG) and tumor marker detection enabled better monitoring of GTD during therapy and remission as well. The objective of our paper was to identify the frequency of GTD metastases, success of their treatment and epidemiological characteristics of patients.
Material and Methods
A retrospective descriptive study included all female patients treated for GTD at the Department of Gynecology and Obstetrics, Clinical Center of Serbia, in the period from January 1 st , 2000 to December 31 st , 2010. All medical histories were reviewed, with particular highlight on metastases, mode of their treatment, type of therapy and epidemiological profile of the patients.
Results
A total of 104 patients were treated for GTD in that 10-year period. Metastases were present in 11 patients (10.6%). They were detected by echosonography and radiography, and if required, by CT scanning. The most common sites of metastases were to lungs (72.2%), and vagina (27.3%), while one patient manifested lung and brain metastases. The average age of patients was 33.9 years. They all had the history of at least one delivery, the mean number being 1.3, and molar pregnancy preceded in 63.6% of patients. The average number of miscarriages was 1.4; 7 patients had no history of miscarriage, and 2 had several miscarriages (7, i.e. 5). The place of reside nce of the majority of them (81.2%) was out of Belgrade territory.
The finding of invasive mole was more frequent than choriocarcinoma (63.6%). The basic characteristics of patients are presented in Table 1 . A combined staging/scoring system, known as FIGO/WHO system, is used for classification of gestational trophoblastic neoplasia. The staging system is ba sed on the anatomic criteria classifying these diseases into four stages (FIGO I-IV) [5, 6] . Each stage is further University Hospital Zemun Stručni članak Pulmonology Ward 1 divided, according to the prognostic scoring system, to low-and high-risk disease. This scoring system sums up all individual scores from 0-4 for each prognostic factor (age, antecedent pregnancy, interval from the index pregnancy in months, β-hCG level before treatment, site of metastases, a number of verified metastases, previous failure of chemotherapy). A total score less than 4 classifies these patients into low-risk category, and over 4 means they are high-risk patients [7, 8] . The mean WHO score was 8.4 (Graph 1). A low WHO score was recorded in 3 patients (WHO score ≤ 4).
All patients were treated by multi-agent therapy, and remission was achieved with the average number of courses of 1.8. No lethal outcome was reported.
In addition, having achieved remission, all patients were followed according to the Protocol for monitoring of GTD patients in the following way: 1) 3 successive normal β-hCG titers taken once a week; 2) determination of β-hCG titer every two weeks over 3 months, then once a month over 6 months, and thereupon every 2 months in the following 6 months and finally every 6 months or once a month in 12 months; 3) frequent pelvic examinations; 4) birth control pills administered in the first year after the remission; 5) check-ups at 6 months over 5 years and once a year after 5 years. None of the patients has been reported to have repeated molar pregnancy so far in the follow-up period.
Discussion
Trophoblastic tissue has tendency for hematogenous dissemination and therefore, the lungs and their vascular system are the most frequent site of metastasis. No less than 85% of metastases are associated with choriocarcinoma [9] [10] [11] [12] . In our sample, all choriocarcinomas metastasized to lungs. Lung metastases generally have good prognosis, with mortality rate of 8% [10, 13] . They subside quickly upon chemotherapy, radiotherapy or surgery. Other sites of metastases are the central nervous system, uterus, vagina, liver and spleen [10] .
Multiple metastases produce mortality rate of 21% and prognostic score depends on the presence of extrapulmonary (particularly to brain) metastasis and whether the metastasis has been preceded by term pregnancy or miscarriage. Brain metastases are associated with high risk of mortality. The majority of these patients die from cerebral hemorrhage, resulting most probably from necrosis of metastatic foci after chemotherapy [4, 9] . In our sample, one patient had primary choriocarcinoma that metastasized to lungs and brain, which was verified by subsequent craniotomy. The patient responded very well to onecourse polychemotherapy, with previous surgical extirpation of the metastatic brain tumor.
It has been established that the mortality is higher if pulmonary metastases are developed after term and ectopic pregnancy and mole-unrelated miscarriage [11] . This is associated with the time interval between antecedent pregnancy and metastases development. If the origin of antecedent pregnancy is not molar, mor- tality is higher because the diagnosis is usually made later than it should be and the treatment is, subsequently, delayed [10, 12] . In our sample, 20% of patients had term pregnancy, and one patient had a miscarriage, but the good outcome of treatment was achieved in all cases, owing to early detection and application of good chemotherapeutical protocol.
Conclusion
Treatment of metastases in gestational trophoblastic diseases depends upon several factors. Combined chemotherapy is a generally accepted mode of treatment. When the initial therapy is individualized, the disease can be cured even in severe cases, and metastatic potential is originally minimized.
